Malignant glioma: should chemotherapy be overthrown by experimental treatments? (Q48422991)

11 February 2018

review article

1 reference

title

Malignant glioma: should chemotherapy be overthrown by experimental treatments? (English)

1 reference

11 February 2018

1 reference

P Hösli

1

1 reference

11 February 2018

A P Sappino

series ordinal

2

1 reference

11 February 2018

N de Tribolet

series ordinal

3

1 reference

11 February 2018

P Y Dietrich

series ordinal

4

1 reference

11 February 2018

publication date

1 June 1998

1 reference

11 February 2018

published in

Annals of Oncology

1 reference

11 February 2018

volume

9

1 reference

11 February 2018

issue

6

1 reference

11 February 2018

page(s)

589-600

1 reference

11 February 2018

The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Assumptions in the radiotherapy of glioblastoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

An analysis of dose-effect relationship in the radiotherapy of malignant gliomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Astrocytes induce blood–brain barrier properties in endothelial cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Distribution of drugs following controlled delivery to the brain interstitium

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Paclitaxel (Taxol) concentrations in brain tumor tissue

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Salvage chemotherapy with paclitaxel for recurrent primary brain tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Phase II study of paclitaxel in patients with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Combination chemotherapy with vincristine (NSC-67574), procarbazine (NSC-77213), prednisone (NSC-10023) with or without nitrogen mustard (NSC-762)(MOPP vs OPP) in children with recurrent brain tumors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Salvage chemotherapy for recurrent primary brain tumors in children

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Molecular pathways in the formation of gliomas.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

The treatment of anaplastic oligodendrogliomas and mixed gliomas.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Autologous bone-marrow transplantation: host effects of high-dose BCNU

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

The p53 gene and its role in human brain tumors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Mdm2 promotes the rapid degradation of p53

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

The retinoblastoma gene is involved in malignant progression of astrocytomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Gene therapy for cancer: what have we done and where are we going?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

The B7 and CD28 receptor families

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Immunobiology of gliomas: new perspectives for therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Inflammatory cytokines in the brain: does the CNS shape immune responses?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

1 reference

7 January 2021

Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008267312782

7 January 2021

Identifiers

DOI

10.1023/A:1008267312782

1 reference

11 February 2018

PubMed ID

9681071

1 reference

11 February 2018